Vaxxinity, Inc.
(VAXX)
Add Watchlist
0.08 USD 0.00
Closed: 17 May, 3:55 pm
Symbol VAXX
Market Cap 10.2M
Price 0.08
Open 0.06
52-wk High 3.10
50 Day Avg 0.45
Earnings Announcement 2024-05-14
Website https://www.vaxxinity.com
Name Vaxxinity, Inc.
Shares Outstanding 126,784,990
Change % 45.9459%
Low 0.06
52-wk Low 0.05
200 Day Avg 0.99
Last Dividend 0.00
Exchange NASDAQ
Volume 1,239,415
Previous Close 0.06
High 0.09
EPS -0.45
PE -0.18
Avg Volume 2,275,998
CUSIP 92244V104
Vaxxinity, Inc. Outlook
Description Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.
Currency USD
ISIN US92244V1044
Industry Biotechnology
Changes 0.03
CUSIP 92244V104
Range 0.05 - 3.10
Beta 2.80
CIK 0001851657

Vaxxinity, Inc. News

03-May-2024 8:24 AM

Why Is Vaxxinity (VAXX) Stock Up 39% Today?

Vaxxinity (NASDAQ: VAXX ) stock is up on Friday with heavy pre-market trading of the biotechnology company's shares. That has more than 21 million shares of VAXX stock changing hands as of this writing.

22-Apr-2024 8:40 AM

Why Is Vaxxinity (VAXX) Stock Down 58% Today?

Vaxxinity (NASDAQ: VAXX ) stock is falling hard on Monday after the biotechnology company announced plans to voluntarily delist its shares from the Nasdaq Exchange. Vaxxinity will file to delist its shares on April 29, 2024.

19-Apr-2024 6:53 PM

Vaxxinity Issues Shareholder Letter

CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu.

19-Apr-2024 4:27 PM

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq Global Market (“Nasdaq”) and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspend its reporting obligations under Section 15(d) of the Exchange Act.

28-Mar-2024 9:23 AM

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

Presentation will address the Company's clinical data in Parkinson's disease Presentation will address the Company's clinical data in Parkinson's disease

27-Mar-2024 4:41 PM

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

07-Mar-2024 10:32 AM

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024

UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson's patients UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson's patients

15-Feb-2024 8:00 AM

Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys.

13-Feb-2024 8:00 AM

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson's disease and preclinical data from its anti-tau program in Alzheimer's disease at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD 2024), taking place March 5-9, 2024 virtually and in Lisbon, Portugal.

30-Jan-2024 8:00 AM

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research collaboration with the University of Florida's (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases. The research, funded by a grant from the state of Florida, aims to further the development of Vaxxinity's active immunotherapies to prevent and mitigate neurodegenerative diseases, having the potential to change the future of treatment by offering people an affordable and accessible therapeutic option.

18-Jan-2024 8:00 AM

Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida

CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the University of Central Florida (UCF) to advance space medicine research. The research, funded by a grant from the State of Florida, aims to further the development of Vaxxinity's active immunotherapies to prevent and mitigate muscle and bone wasting, which are well known health challenges related to long-term spaceflight, and which share biological mechanisms implicated in highly prevalent age-related diseases.